“…Multiple in vivo studies of various animal species have shown the mitigation capabilities of binders following the administration of synthetic or natural mycotoxins via diet, whereas the binder’s efficacy has been appraised based on an observed improvement in animal performance [ 26 , 27 , 28 ]. Other animal studies have primarily focused on indirect, often non-specific/shared biomarkers of exposure as an outcome in the evaluation of mitigation strategies, such as measuring changes in intestinal health using histopathological assessment [ 29 ], modification of blood chemistry [ 30 , 31 , 32 , 33 ], changes in immunological titers [ 34 , 35 , 36 , 37 , 38 ], changes in microbiota [ 32 , 39 ], genomic and antioxidant markers [ 40 , 41 , 42 , 43 ], and changes in organ morphology [ 44 , 45 ]. However, only a few in vivo studies have measured toxin partitioning in the animal body and revealed the pharmacokinetics of toxin accumulation in different tissues and digesta [ 46 , 47 , 48 ].…”